Solid Biosciences Announces $240 Million Private Placement Financing

Solid Biosciences ( (SLDB) ) has issued an update.

On March 6, 2026, Solid Biosciences Inc. entered into a securities purchase agreement with institutional accredited investors for a private placement of 14,973,257 common shares at $5.61 and pre-funded warrants for 27,807,482 shares at $5.609, raising approximately $240 million in gross proceeds and $226.8 million in net proceeds, with closing expected around March 9, 2026. The deal, which includes major life sciences investors and trading lock-ups until March 11, 2026, also provides for resale registration rights and liquidated damages if registration deadlines are missed, while warrant terms cap individual ownership levels to prevent excessive concentration.

The company structured the offering as an exempt private placement to accredited and qualified institutional buyers, with the securities initially unregistered and subject to resale restrictions under U.S. federal securities laws. Based on its current operating plan, Solid Biosciences estimates that the net proceeds from this financing, combined with existing cash and investments, will fund operating and capital needs into the first half of 2028, though the company does not expect this cash runway to cover completion of development for any product candidates and may need further funding sooner if assumptions change.

The most recent analyst rating on (SLDB) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Solid Biosciences stock, see the SLDB Stock Forecast page.

Spark’s Take on SLDB Stock

According to Spark, TipRanks’ AI Analyst, SLDB is a Neutral.

The score is held down primarily by very weak fundamentals—zero TTM revenue, widening losses, and significant ongoing cash burn—despite a relatively low-debt balance sheet. Technicals are moderately supportive with neutral-to-positive momentum, but valuation remains difficult to justify on earnings due to the negative P/E and no dividend.

To see Spark’s full report on SLDB stock, click here.

More about Solid Biosciences

Solid Biosciences Inc. is a U.S.-based biotechnology company focused on developing therapies for rare neuromuscular and genetic diseases. The company advances a pipeline of product candidates aimed at addressing significant unmet medical needs, relying on external capital to fund research, development, and related corporate activities in a competitive life sciences market.

Average Trading Volume: 1,045,321

Technical Sentiment Signal: Buy

Current Market Cap: $437.1M

For an in-depth examination of SLDB stock, go to TipRanks’ Overview page.